This month,Fabre-Kramer Pharmaceuticals’s antidepressant Exxua (gepirone hydrochloride) should finally receive its first regulatory approval, more than 20 years after it was initially rejected by the US Food and Drug Administration.
More than a dozen clinical trials have been conducted and the drug’s development history goes back to the mid-80s. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?